Literature DB >> 1012333

Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.

P C Waldmeier, L Maître.   

Abstract

Behavioural and somatic responses to L-DOPA in rats are potentiated by short-term pretreatment with pargyline. It was therefore of interest to study the influence of the delay between pargyline pretreatment and L-DOPA-injection on the fate of the latter in rat brain. In rats treated with pargyline (50 mg/kg s.c.), the half-lives of recovery of striatal MAO activity and normal endogenous contents of homovanillic and 3,4-dihydroxyphenylacetic acids in striatum ranged from 9 to 14 days. The same treatment led to a marked increase (50-100-fold) in the accumulation of 3H-methoxytyramine in whole brain and, though less so, in 3H-dopamine formed from i.v. 3H-DOPA. Recovery from this effect of pargyline, however, was more rapid with a half-life of 15-19 h. Similar changes were observed when 3H-DOPA or 3H-dopamine was injected intracisternally, indicating that the phenomenon did not take place in the cerebral blood capillary walls, which are known to contain DOPA decarboxylase and MAO activities. The only labelled deaminated metabolite of dopamine in the brain after 3H-DOPA i.v. was 3H-homovanillic acid, which was strongly reduced 2 h after pargyline, but normalized after 24 h of pretreatment with the MAO inhibitor. When 3H-alpha-methyldopa instead of 3H-DOPA was injected, no increase in 3H-alpha-methyldopamine and its O-methylated derivative was produced by pargyline pretreatment. Moreover, in an experiment in which the animals were pretreated with pargyline at various times up to 21 days, a second injection of the MAO inhibitor 1.5 h before 3H-DOPA restored the increase in 3H-DA + 3H-MT observed with a single treatment with pargyline 1.5 h before the labelled amino acid. These results suggest that this short-lasting effect of the MAO inhibitor is related to the MAO inhibitory properties of the drug. The threshold dose of pargyline for producing the short-term effect was about 10 times higher than that for an overall MAO (DA deaminating) inhibition. However, it seems unlikely that this was due to near maximal inhibition of overall MAO activity, i.e. that it occurred only when MAO was inhibited by more than, say, 90%. The data reported suggest the existence of a small portion of an additional form of MAO with a rapid turnover and with a marked capacity to deaminate dopamine or methoxytyramine, and a greater resistance to inhibition by pargyline than cerebral MAO in general.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1012333     DOI: 10.1007/bf00507845

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE.

Authors:  R J WURTMAN; J AXELROD
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

2.  Effect of L-DOPA and N-methyl-N-benzyl-2-propynylamine. HC1 on DOPA, dopamine, norepinephrine, epinephrine and serotonin levels in mouse brain.

Authors:  R G WIEGAND; J E PERRY
Journal:  Biochem Pharmacol       Date:  1961-08       Impact factor: 5.858

3.  The oxidation of adrenaline and other amines.

Authors:  H Blaschko; D Richter; H Schlossmann
Journal:  Biochem J       Date:  1937-12       Impact factor: 3.857

Review 4.  Neuronal monoamine oxidase: specific enzyme types and their rates of formation.

Authors:  N H Neff; C Goridis
Journal:  Adv Biochem Psychopharmacol       Date:  1972

Review 5.  Multiple forms of mitochondrial monoamine oxidase.

Authors:  M B Youdim
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

6.  Individual elution of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from a single, strong cation exchange column, by means of mineral acid-organic solvent mixtures.

Authors:  C V Atack; T Magnusson
Journal:  J Pharm Pharmacol       Date:  1970-08       Impact factor: 3.765

7.  Rates of recovery of irreversibly inhibited monoamine oxidases: a measure of enzyme protein turnover.

Authors:  G Planz; K Quiring; D Palm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

8.  Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.

Authors:  P C Waldmeier; A Delini-Stula; L Maître
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

9.  End-product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norepinephrine synthesis.

Authors:  S Spector; R Gordon; A Sjoerdsma; S Udenfriend
Journal:  Mol Pharmacol       Date:  1967-11       Impact factor: 4.436

10.  The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse.

Authors:  G F Murphy; D Robinson; D F Sharman
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

View more
  4 in total

1.  In vivo labelling and axonal transport of monoamine oxidase in the rat basal ganglia using radioactive pargyline.

Authors:  J B Gramsbergen; J B Sebens; J Korf
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

2.  Neurochemical investigations of the interaction of N,N-dimethyltryptamine with dopaminergic system in rat brain.

Authors:  P C Waldmeier; L Maître
Journal:  Psychopharmacology (Berl)       Date:  1977-04-29       Impact factor: 4.530

Review 3.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

4.  The neuropharmacological profile of N-methyl-N-propargyl-2-aminotetralin: a potent monoamine oxidase inhibitor.

Authors:  B Hazelhoff; J B De Vries; D Dijkstra; W de Jong; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.